Lab and mouse research suggests that SH2B1, a protein found mainly in liver cells, helps keep fat from piling up in the liver. According to research reviewed by Gram, mice fed a high-fat diet that had less SH2B1 in their livers developed more liver fat and more liver damage. The protein may be a future target for fatty liver disease, but it has not yet been tested in people.

Researchers wanted to know whether a protein called SH2B1 helps control how fat is stored in the liver. Gram Research analysis of this study found that SH2B1 levels were lower in people and mice with fatty liver disease. When scientists lowered SH2B1 in liver cells exposed to fats, the cells stored more fat. When they raised SH2B1, the cells stored less. In mice eating a high-fat diet, reducing SH2B1 in the liver led to more fat buildup and more liver damage. The protein appeared to work partly through a cell recycling pathway involving a protein called LAMP2A. These results come from lab cells and mice, so they cannot yet show whether the same effect happens in people. Still, the work points to SH2B1 as a possible future target for fatty liver disease.

Key Statistics

A 2026 study published in Life Sciences found that mice fed a high-fat diet developed more liver fat and liver injury when SH2B1 was reduced in their livers.

A 2026 study in liver cells exposed to palmitate and oleate found that lowering SH2B1 increased levels of the fat-coating protein PLIN2 and increased fat storage, while raising SH2B1 produced the opposite effect.

The Quick Take

  • What they studied: Whether a liver protein called SH2B1 helps control how fat is stored inside liver cells, and how it does this, in fatty liver disease.
  • Who participated: The study used existing human and mouse gene activity datasets, liver cells grown in the lab, and laboratory mice fed a high-fat diet. The abstract does not report the exact number of animals or samples.
  • Key finding: Lower SH2B1 was linked to more fat storage in liver cells and more fat and liver damage in mice. Higher SH2B1 was linked to less fat storage. The effect appeared to run partly through a protein called LAMP2A, which influences a fat-storage protein called PLIN2.
  • What it means for you: This research does not yet mean you should change your diet or take any supplement because of SH2B1. It helps scientists understand how fat builds up in the liver, which could guide future treatments. Anyone concerned about fatty liver should talk with a doctor.

The Research Details

The researchers began by searching existing public databases of gene activity from people and mice with fatty liver. They looked at liver cells from these datasets to see how much SH2B1 was present and which other genes changed alongside it. This step helped them spot connections worth testing.

Next, they grew liver cells in the lab and exposed them to two common fats, palmitate and oleate, which mimic the effects of a rich diet. In these cells, they turned SH2B1 production down or up and measured how much fat was stored and how much PLIN2 was present. They also reduced LAMP2A, a protein involved in breaking down and recycling cell parts, to test whether it was needed for SH2B1’s effects.

Finally, the team tested the idea in living mice. They fed the mice a high-fat diet, then used a harmless viral carrier to lower SH2B1 in the liver. They then compared fat buildup and liver health with mice that did not have this change. The researchers also used computer modeling and lab tests to check whether SH2B1 physically binds to another protein, HSC70, and whether the two appear in the same parts of the cell.

Using several approaches together strengthens the findings. Public datasets show what happens in real human and mouse livers, lab cell experiments show cause and effect in a controlled setting, and animal experiments test whether the effect appears in a whole living body. When the same pattern shows up across these levels, scientists have more reason to take the idea seriously. Each approach also has limits, so the findings still need confirmation in people.

The study was published in Life Sciences, a peer-reviewed scientific journal, which means outside experts reviewed it before publication. It used several complementary methods, including public data, cell experiments, animal experiments, and protein tests. The abstract does not report the number of animals or cell experiments, so the size of the study is difficult to judge from the summary alone. Results from cells and mice often do not carry over to people, so these findings are an early step rather than proof.

What the Results Show

The researchers first found that SH2B1 was present at lower levels in fatty livers from both people and mice. Most of the SH2B1 was found in liver cells called hepatocytes, which do most of the work of processing fat. Across one human dataset, levels of PLIN2 were higher when SH2B1 was lower. PLIN2 is a protein that coats fat droplets inside cells, and higher amounts are linked to more fat storage.

In the lab, exposing liver cells to palmitate and oleate lowered SH2B1 and raised PLIN2, and fat accumulated in the cells. When the team reduced SH2B1, PLIN2 and fat storage went up. When they increased SH2B1, both went down. This pattern, seen in both directions, suggests that SH2B1 actively influences how much fat the cells hold.

The team also found that SH2B1 and a protein called HSC70 appear to physically connect and sit in the same parts of the cell. Changing SH2B1 also changed levels of LAMP2A, a protein involved in cell recycling. When LAMP2A was reduced, the fat-lowering effect of extra SH2B1 was weakened, which suggests LAMP2A is part of the pathway.

In mice, lowering SH2B1 in the liver made a high-fat diet cause more fat buildup and more liver injury. These mice also had less LAMP2A and more PLIN2 in their livers. Together, these results point to a chain of events in which SH2B1 helps maintain LAMP2A, which in turn keeps PLIN2 in check and limits fat storage.

The study showed that SH2B1’s effects on fat storage were visible at several levels, from gene activity to protein levels to whole-animal liver health. This consistency matters because it suggests the protein plays a real role rather than a side effect. The finding that liver injury worsened in mice, not just fat buildup, also suggests that SH2B1 may affect liver health more broadly.

Earlier research has linked SH2B1 to body weight, insulin response, and energy use, so the protein’s role in metabolism was already suspected. This study adds a more specific picture by showing that SH2B1 influences liver fat storage through a particular cell recycling pathway. It also builds on known links between PLIN2 and fatty liver disease. The study is new in connecting these pieces together, but it is still early work that needs to be repeated and extended.

Most of the evidence comes from cultured liver cells and mice, and results in these settings do not always apply to people. The abstract does not state how many animals or samples were used, which makes the strength of the evidence harder to judge. The mice were fed a high-fat diet for a set time, so the findings may not reflect how fatty liver develops over many years in people. Some of the connections, such as the link between SH2B1 and HSC70, were tested with computer modeling and a limited set of lab experiments, which means they still need confirmation. The study also does not test whether any drug or treatment can safely change SH2B1 levels in people.

The Bottom Line

At this stage, there are no practical recommendations for patients based on SH2B1 alone. The evidence is preliminary and comes from lab and animal work, so confidence that the same effect will happen in people is low to moderate. The findings are most useful as a guide for future research into treatments. Proven steps to protect liver health, such as losing excess weight, limiting sugary drinks and alcohol, and staying active, remain strongly supported by much larger body of evidence.

Researchers studying fatty liver disease, drug developers looking for new targets, and clinicians who follow liver health will find this work relevant. People who have been diagnosed with fatty liver disease may find it encouraging to know that scientists are studying how fat builds up in the liver, but they should not change their care based on this study. Anyone without fatty liver should focus on proven habits rather than waiting for new treatments.

Lab and animal findings like these usually take many years to reach patients. Researchers would need to confirm the results, test safety, and run human clinical trials before any SH2B1-based treatment could be considered. This process commonly takes a decade or more, and many promising laboratory findings never become approved treatments.

Frequently Asked Questions

What is SH2B1 and how does it relate to fatty liver disease?

SH2B1 is a protein found mainly in liver cells. In lab and mouse studies, lower SH2B1 levels were linked to more fat storage in the liver and more liver damage, suggesting it helps regulate fat buildup in the liver.

Can changing SH2B1 levels treat fatty liver disease in people?

Not yet. Research on SH2B1 so far has been done in liver cells and mice. No human treatment targeting SH2B1 has been tested, so it is too early to know whether it could help people with fatty liver disease.

What is the best proven way to protect the liver from fat buildup?

Losing excess weight, limiting sugary drinks and alcohol, eating less processed food, and staying physically active are well supported by evidence. Many people benefit from losing even 5 to 10 percent of body weight, and a doctor can guide the approach.

What did the mouse study find about liver fat and diet?

In mice fed a high-fat diet, reducing SH2B1 in the liver worsened fat buildup and liver injury. These mice also had lower levels of LAMP2A and higher levels of PLIN2, a protein that helps store fat in cells.

Want to Apply This Research?

  • Track measurable habits that are known to affect liver fat, such as daily servings of sugary drinks, alcohol days per week, minutes of moderate activity, and waist measurement once a week. If you have a diagnosis, log the results of any liver tests your doctor orders, such as ALT or ultrasound findings, and bring the data to appointments.
  • Use the app to set one small, realistic goal, such as replacing one sugary drink a day with water or walking for 20 minutes after dinner. Review your weekly log to see patterns and celebrate consistent progress. Remember that these habits support liver health based on established evidence, not on SH2B1 itself.
  • Review your habit and measurement logs monthly and share trends with your healthcare provider during routine checkups. Track changes over several months rather than days, since liver fat changes slowly. Update your goals as your doctor recommends, and treat any new supplement or treatment claim involving SH2B1 with caution until human research supports it.

This article summarizes a laboratory and animal research study and is for general education only. The findings come from liver cells and mice and have not been tested in human clinical trials, so they should not be used to make decisions about diagnosis, treatment, diet, or supplements. Anyone with fatty liver disease or liver concerns should consult a qualified healthcare provider before making changes to their care.

This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.

Source: SH2B1 modulates hepatic lipid droplet homeostasis and is associated with HSC70/LAMP2A-related PLIN2 regulation in metabolic dysfunction-associated fatty liver disease. , Life sciences (2026). PubMed 43035120 | DOI
Topics
SH2B1 protein fatty liver disease MAFLD liver fat storage PLIN2 LAMP2A liver health research high-fat diet mice